UB293
ProductClarithromycin Tablets
Strength0.25g
IndicationsUpper respiratory tract infection; Lower respiratory tract infection; Skin and soft tissue infection; Localized infection; Disseminated infection; Mixed infection; Odontogenic infection; Helicobacter pylori infection
TherapeuticsInfectious Diseases
GMPCN - NMPA
RegistrationChina
ModalitiesSmall Molecule
Exclusive Summary
- - Core patents and data exclusivity have long expired; 0.25 g IR tablets face no meaningful IP barriers in most markets, enabling rapid distribution deals.
- - Key use-cases span H. pylori eradication, CAP combination therapy, and MAC treatment/prophylaxis, creating tens of millions of treatment opportunities annually.
- - Listed on the WHO Essential Medicines List (for H. pylori eradication) and endorsed by major guidelines under defined conditions, ensuring strong clinical acceptance.
- - Although highly genericized, differentiation is achievable via Zone IVb stability, dissolution equivalence, therapy-ready packs (e.g., 28/56 tablets), and reliable supply.
- - Typically 80–95% cheaper than originator brands, supporting volume growth across tenders and retail with attractive distributor margins.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →